Literature DB >> 30610319

Extreme Lateral Approach to the Craniovertebral Junction: An Update.

Nabeel S Alshafai1, Tomasz Klepinowski2,3.   

Abstract

INTRODUCTION: The term 'extreme lateral approach' (ELA) was first introduced by Sen and Sekhar relatively recently (in 1990). Its definition varies and remains controversial, but it generally entails more aggressive bony removal than the far lateral approach (FLA). GOAL: In this paper we review the relevant literature and weigh up the advantages and disadvantages of this approach. We propose methods to manage the complications resulting from the more invasive character of the ELA. Some modern trends regarding how to definitely distinguish the ELA from the FLA are also presented.
METHODS: Using the PubMed database, literature was collected on the relevant topics and subsequently reviewed. All up-to-date tips and tricks were carefully gathered, and current morbidity and mortality rates were obtained, as well as further perspectives. RESULTS AND
CONCLUSION: The morbidity associated with the ELA remains higher than that associated with the FLA, but the mortality nowadays is comparable. The ELA undoubtedly is a challenging procedure requiring deep insight into the relevant anatomy and its normal variants.

Entities:  

Keywords:  Craniovertebral junction; ELITE; Extreme lateral approach; Meningiomas; Vertebral artery transposition

Mesh:

Year:  2019        PMID: 30610319     DOI: 10.1007/978-3-319-62515-7_25

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  2 in total

Review 1.  Foramen magnum meningiomas: a systematic review and meta-analysis.

Authors:  Luca Paun; Renato Gondar; Paola Borrelli; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2021-01-28       Impact factor: 3.042

2.  Prevalence of high-riding vertebral arteries and narrow C2 pedicles among Central-European population: a computed tomography-based study.

Authors:  Tomasz Klepinowski; Natalia Żyłka; Bartłomiej Pala; Wojciech Poncyljusz; Leszek Sagan
Journal:  Neurosurg Rev       Date:  2021-02-09       Impact factor: 3.042

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.